Bain Capital to acquire UK's Vitabiotics, including India business Meyer Organics

Global private investment firm Bain Capital has agreed to acquire Vitabiotics, the UK's largest vitamin company, including its UK operations and the wider VB Group, which comprises Meyer Organics in India and operations across Africa, including VB Egypt. 

The financial details of the transaction were not disclosed. The acquisition marks a key milestone in Vitabiotics' 55-year history and is aimed at accelerating the company's international expansion. Bain Capital said the partnership would combine its healthcare and consumer sector expertise with one of the world's leading independent vitamins, minerals and supplements (VMS) companies to drive long-term global growth. 

Despite the ownership change, Vitabiotics said its UK operations will remain at the core of its business, with no immediate changes to day-to-day operations. The company plans to continue investing in digital capabilities, e-commerce, international distribution, supply chain resilience, and new product development. 

Given Vitabiotics' extensive international presence, the investment will be led by Bain Capital's Asia Private Equity team, supported by its global platform. The firm said it will leverage its expertise in India and other key markets to help expand the company's footprint across regions including the Middle East and North Africa (MENA) and China. 

Founded in 1971 by scientist and entrepreneur Professor Kartar Lalvani, Vitabiotics has built a portfolio of science-led nutritional supplements, including brands such as Pregnacare, Perfectil, Wellman, Wellwoman, Osteocare, and the Ultra range. 

Under the leadership of Tej Lalvani, Group Chief Executive Officer, the company has significantly expanded its global presence through new product launches and strategic partnerships. Following the completion of the transaction, Professor Kartar Lalvani will assume the honorary role of Chairman Emeritus in recognition of his contribution to the business. 

Vitabiotics has established a strong presence in several key vitamins and supplements markets, including India, China, Egypt and the wider MENA region, supported by healthcare professional trust and local market expertise. 

Tej Lalvani, Group CEO of Vitabiotics, said the transaction marks a defining moment for the company. "This direction is not about changing who we are; it is about accelerating what we can become. With Bain Capital's global expertise and investment behind us, we have a unique opportunity to expand internationally, accelerate innovation and take our trusted brands to millions more consumers, while staying true to the science, quality and values that have defined Vitabiotics for more than 55 years," he said. 

Pawan Singh, Partner at Bain Capital, said Vitabiotics represents the type of science-led consumer healthcare business the firm seeks to back. 

"Vitabiotics is exactly the type of business we support—a trusted, science-led brand platform with category leadership, strong healthcare professional credibility and meaningful presence across the UK, India, the Middle East, Africa and China. Our India team has deep experience partnering with healthcare and consumer businesses, and we look forward to supporting Vitabiotics' next phase of growth," he said. 

Rishi Mandawat, Partner at Bain Capital, said the firm sees significant potential to strengthen Vitabiotics' global platform by investing in innovation, e-commerce, international distribution and operational capabilities.